ReviewCureus2026
Artificial Intelligence in the Detection, Characterization, and Management of Renal Masses: A Narrative Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney tumors are being found more often today because CT and MRI scans are widely used and kidney masses are frequently discovered by chance. Many of these masses are benign. However, most patients still undergo surgery because doctors cannot confirm the diagnosis from imaging alone. Artificial intelligence (AI) refers to computer systems that perform tasks normally requiring human intelligence, including machine learning, in which algorithms learn patterns directly from data, and radiomics, in which quantitative features are extracted from medical images to support diagnosis. These tools offer new ways to improve how kidney masses are detected, characterized, and treated. This narrative review summarizes current evidence on AI applications across the renal mass pathway, covering automated detection, imaging-based characterization, pathological staging, prognosis prediction, and AI-assisted surgical planning, while also outlining current limitations and future research directions. A review of the English-language literature was performed using PubMed and MEDLINE, with studies published between 2018 and 2026 prioritized. AI shows strong performance across all stages of the renal mass pathway. Deep learning models accurately detect and segment renal masses on CT and MRI. Radiomics-based classifiers distinguish benign from malignant lesions and predict tumor subtype without biopsy. Multimodal AI models predict survival with high accuracy and outperform established clinical scoring systems. AI-assisted surgical planning tools support nephron-sparing surgery and predict postoperative kidney function. Wider clinical use requires better prospective validation, more diverse datasets, and improved model transparency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.